Detalhe da pesquisa
1.
MCU controls melanoma progression through a redox-controlled phenotype switch.
EMBO Rep
; 23(11): e54746, 2022 11 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36156348
2.
Heterogeneity in Melanoma.
Cancer Treat Res
; 167: 1-15, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-26601857
3.
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Nat Cancer
; 4(9): 1292-1308, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37525015
4.
Persister state-directed transitioning and vulnerability in melanoma.
Nat Commun
; 13(1): 3055, 2022 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35650266
5.
Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma.
JCO Precis Oncol
; 32020.
Artigo
Inglês
| MEDLINE | ID: mdl-32914028
6.
Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells.
J Invest Dermatol
; 139(12): 2506-2516.e10, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31229500
7.
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Nat Cancer
; 4(9): 1395, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37580519
8.
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.
Cell Rep
; 21(7): 1936-1952, 2017 Nov 14.
Artigo
Inglês
| MEDLINE | ID: mdl-29141224
9.
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.
Cell Rep
; 21(7): 1953-1967, 2017 Nov 14.
Artigo
Inglês
| MEDLINE | ID: mdl-29141225
10.
Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.
Pigment Cell Melanoma Res
; 29(3): 317-28, 2016 May.
Artigo
Inglês
| MEDLINE | ID: mdl-26850518
11.
PIM kinases as therapeutic targets against advanced melanoma.
Oncotarget
; 7(34): 54897-54912, 2016 Aug 23.
Artigo
Inglês
| MEDLINE | ID: mdl-27448973
12.
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Clin Cancer Res
; 22(7): 1592-602, 2016 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26673799
13.
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
J Clin Invest
; 126(5): 1834-56, 2016 05 02.
Artigo
Inglês
| MEDLINE | ID: mdl-27043285
14.
Rhenium complexes with visible-light-induced anticancer activity.
ChemMedChem
; 8(6): 924-7, 2013 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-23568508
15.
Advanced glycation end products overload might explain intracellular cobalamin deficiency in renal dysfunction, diabetes and aging.
Med Hypotheses
; 77(5): 884-8, 2011 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-21880434